Gigagen, Inc. — Department of Health and Human Services SBIR Phase I: <p>DESCRIPTION (provided by applicant): Specific Aim of this Innovative Molecular Analysis
Gigagen, Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $249,077
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PAR13-327
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
<p>DESCRIPTION (provided by applicant): Specific Aim of this Innovative Molecular Analysis Technologies (IMAT) SBIR Phase I grant proposal is to show the feasibility of a high-throughput molecular technology for discovery of monoclonal antibody (mAb) drugs for oncology from human B cell repertoires. Drug companies spend up to 5 billion to produce a single FDA-approved monoclonal antibody, or mAb (DiMasi and Grabowski, 2007; Nelson et al., 2010). High mAb development cost is at least partly due to the high failure rate of candidates. A technology that improves mAb selection by just 10% before entering clinical development could save the drug industry ~ 400 million per FDA- approved mAb. Immune systems are test tubes that constantly select for antibodies withstrong potential as drugs. GigaLink will be a research service for drug discovery programs that leverages these antibody selection test tubes. In mouse systems, our technology could eventually replace B cell immortalization. In human systems, our techn</p>